

Review of: "Comparative analysis between Polymerized Type I Collagen (Fibroquel) and Baricitinib as a potential treatment for moderate-severe COVID-19 in outpatients and inpatients"

Qian Li¹

¹ University of California, Los Angeles

Potential competing interests: No potential competing interests to declare.

The analysis compared the effects of Polymerized Type I Collagen (Fibroquel) and Baricitinib for patients with moderate-severe COVID-19. This is an interesting study on the hot topic. Though the study was conducted in a small population, it has big value for the investigation of COVID-19 treatments, especially for cases with poor progress. From my point of view, I have the following concerns and comments.

1. I am wondering whether Fibroquel was administered for the Polymerized Type I Collagen (PTIC) group, it was just mentioned in the title.
2. I suggest giving a brief comparison of the pharmacological properties between PTIC and Baricitinib in the introduction part.
3. What is the definition of modest-severe COVID-19 cases in the study?
4. Based on the statistical results, there are differences in gender, age, and major previous comorbidities between the two groups. How to understand the potential influence of the for-mentioned differences on the treatment effects?
5. In the conclusion part, the authors mentioned TIPC has immunomodulatory potential, what are the parameters/indicators for immunomodulatory potential in the study?
6. What are the limitations of the study?
7. To improve the quality of the paper, it would be helpful to include previous evidence of TIPC for treatments of COVID-19 or related diseases and perform further discussion.
8. Pay special attention to minor mistakes in grammar or spelling, e.g.
 - 1) Abstract, Methods, line 4. It is better to use 'the other' instead of 'another'.
 - 2) Introduction, line 4. 'are Very few' should be 'are very few'.

